Leenar Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 3 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -507.20%
(FY 2023)
- Ebitda -445.98%
(FY 2023)
- Net Worth -633.41%
(FY 2023)
- Total Assets -9.36%
(FY 2023)
About Leenar Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Narasimha Goli, Saritha Kesari, and Kesari Reddy serve as directors at the Company.
- CIN/LLPIN
U24100TG2021PTC150646
- Company No.
150646
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Apr 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Leenar Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kesari Reddy  | Managing Director | 16-Apr-2021 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Narasimha Goli | Director | 16-Apr-2021 | Current |
| Saritha Kesari | Director | 24-Sep-2021 | Current |
Financial Performance of Leenar Life Sciences.
Leenar Life Sciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 507.2% decrease in profit. The company's net worth observed a substantial decline by a decrease of 633.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Leenar Life Sciences?
Unlock access to Leenar Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Sai Siri Packaging Private LimitedActive 3 years 9 monthsSaritha Kesari and Kesari Reddy are mutual person
Rui Laboratories Private LimitedActive 7 years 2 monthsNarasimha Goli, Saritha Kesari and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Leenar Life Sciences?
Leenar Life Sciences has a workforce of 11 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Leenar Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Leenar Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
